Preemptive Medicine for Cerebral Aneurysms.
Tomohiro Aoki, Kazuhiko Nozaki
https://pubmed.ncbi.nlm.nih.gov/27053328/Actively Recruiting
Led by Beijing Tiantan Hospital · Updated on 2026-09-16
280
Participants Needed
1
Research Sites
17 weeks
Total Duration
Intracranial aneurysm is a common cerebrovascular condition that can be treated with various methods, including surgery and endovascular approaches. Among these, flow diverters have gained attention for their unique way of redirecting blood flow to encourage clot formation within the aneurysm, aiming to treat it effectively. Devices like the Pipeline flow diverter have shown safety and effectiveness and are becoming preferred options for managing intracranial aneurysms. This study evaluates a new generation of flow diverter stents such as Pipeline Shield and Lattice for treating intracranial wide-neck aneurysms in China. Patients will receive implantation of these devices according to their instructions for use and local medical practices. Alongside the stent, participants will take dual antiplatelet therapy for at least 3 to 6 months after the procedure. This is a prospective, multicenter, single-group study involving about 280 patients across 15 sites. Participants will be followed up with clinical evaluations and imaging tests like DSA or CTA at 30 days, 6 months, 1 year, and annually up to 4 years after the procedure. The main outcome measured is the rate of complete aneurysm occlusion one year after treatment. Safety and effectiveness will be monitored throughout, including assessments of neurological function using the Modified Rankin Scale. The total study duration extends until the end of 2030.
CONDITIONS
A Multicenter Prospective Study of New Flow Diverter Stent on the Treatment of Intracranial Aneurysms in China
H
Hengwei Jin
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beijing Tiantan Hospital
Lead Sponsor
Huashan Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are evaluated to confirm eligibility for the trial based on medical history, diagnosis, and other criteria.
1 to 2 visits
Duration - Initial procedure with ongoing medication for 3 to 6 months
Participants receive the new flow diverter stent implant and follow dual antiplatelet therapy as prescribed.
Follow-up visits at 30 days and 6 months
Duration - Up to 4 years
Participants undergo clinical assessments and imaging tests to monitor aneurysm healing and neurological function up to 4 years post-procedure.
Visits at 1 year and annually thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Tomohiro Aoki, Kazuhiko Nozaki
https://pubmed.ncbi.nlm.nih.gov/27053328/Fawaz Al-Mufti, Krishna Amuluru, Chirag D Gandhi...
https://pubmed.ncbi.nlm.nih.gov/27160270/Beijing Tiantan Hospital
Lead Sponsor
Huashan Hospital
Collaborating Sponsor